Clinical trial
Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification
NCT00124709 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00124709 |
|---|---|
| Title | Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification |
| Official title | An Investigation of the Safety and Efficacy of Elidel® 1% Cream in Atopic Disease Modification, Assessed in a 3-year Randomized Double-blind Vehicle Controlled Phase to Evaluate Effects on Atopic Dermatitis in Infants, and a 2-3 Year Open-label Phase to Evaluate the Effect of Early Intervention… |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Atopic Dermatitis |
| Intervention type | Drug |
| Interventions | Pimecrolimus, Corticosteroid |
| Enrollment | 1,091 |
| Start date | Oct 1, 2003 |
| Primary completion | Jan 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Jul 28, 2005 |
| Last update posted | Mar 23, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: